Literature DB >> 22587522

Prevention of antibody-mediated kidney transplant rejection.

Christian Morath1, Gerhard Opelz, Martin Zeier, Caner Süsal.   

Abstract

There is increasing evidence that antibody-mediated rejection is the major cause of late kidney graft failure. Prevention of antibody-mediated allograft damage has therefore become an important issue in kidney transplantation. Such prevention starts already before transplantation with the avoidance of sensitizing events. When a patient is already sensitized, precise characterization of alloantibodies and exact HLA typing of the donor at the time of transplantation are mandatory. To ensure timely and successful transplantation of highly sensitized patients, desensitization, and inclusion in special programs such as the Eurotransplant Acceptable Mismatch Program should be considered. After transplantation, close monitoring of kidney function, testing for the de novo development or changing characteristics of alloantibodies, and attention to non-adherence to immunosuppression is obligatory. In the current overview, we discuss the currently available measures for the prevention of antibody-mediated kidney graft rejection.
© 2012 The Authors. Transplant International © 2012 European Society for Organ Transplantation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22587522     DOI: 10.1111/j.1432-2277.2012.01490.x

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  6 in total

1.  Antibody-mediated rejection in young kidney transplant recipients: the dilemma of noncompliance and insufficient immunosuppression.

Authors:  Oriol Bestard; Minnie M Sarwal
Journal:  Pediatr Nephrol       Date:  2014-12-11       Impact factor: 3.714

Review 2.  Rationale for Surrogate Endpoints and Conditional Marketing Authorization of New Therapies for Kidney Transplantation.

Authors:  Maarten Naesens; Alexandre Loupy; Luuk Hilbrands; Rainer Oberbauer; Maria Irene Bellini; Denis Glotz; Josep Grinyó; Uwe Heemann; Ina Jochmans; Liset Pengel; Marlies Reinders; Stefan Schneeberger; Klemens Budde
Journal:  Transpl Int       Date:  2022-05-20       Impact factor: 3.842

Review 3.  Diagnosis and management of antibody-mediated rejection: current status and novel approaches.

Authors:  A Djamali; D B Kaufman; T M Ellis; W Zhong; A Matas; M Samaniego
Journal:  Am J Transplant       Date:  2014-01-08       Impact factor: 8.086

4.  Living Donor Kidney Transplantation in Patients With Donor-Specific HLA Antibodies After Desensitization With Immunoadsorption.

Authors:  Florian Kälble; Caner Süsal; Luiza Pego da Silva; Claudius Speer; Louise Benning; Christian Nusshag; Lien Pham; Hien Tran; Matthias Schaier; Claudia Sommerer; Jörg Beimler; Arianeb Mehrabi; Martin Zeier; Christian Morath
Journal:  Front Med (Lausanne)       Date:  2021-12-17

Review 5.  Late and chronic antibody-mediated rejection: main barrier to long term graft survival.

Authors:  Qiquan Sun; Yang Yang
Journal:  Clin Dev Immunol       Date:  2013-10-08

Review 6.  Kidney Transplantation: The Challenge of Human Leukocyte Antigen and Its Therapeutic Strategies.

Authors:  Tilahun Alelign; Momina M Ahmed; Kidist Bobosha; Yewondwossen Tadesse; Rawleigh Howe; Beyene Petros
Journal:  J Immunol Res       Date:  2018-03-05       Impact factor: 4.818

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.